Cargando…

An unusual case of primary hepatic lymphoma with dramatic but unsustained response to bendamustine plus rituximab and literature review

OBJECTIVES: Primary hepatic lymphoma is an uncommon cause of hepatic space-occupying lesions. METHODS: We describe the case of a 73-year-old man with primary hepatic lymphoma, who presented with a low-grade fever and lower limb weakness which had progressed in the past 2 months. RESULTS: Abdominal u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Sih-Han, Chen, Yin-Kai, Yu, Shan-Chi, Wu, Ming-Shiang, Wang, Hsiu-Po, Tseng, Ping-Huei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448865/ https://www.ncbi.nlm.nih.gov/pubmed/28596829 http://dx.doi.org/10.1177/2050313X17709190

Ejemplares similares

Evidence of bendamustine plus rituximab for old and frail patients with aggressive B-cell lymphoma
por: Schalk, Enrico, et al.
Publicado: (2023)

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
por: Murayama, Kayoko, et al.
Publicado: (2022)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
por: Bega, Giulia, et al.
Publicado: (2021)

Severe Liver Damage and Nonallergic Bronchitis with Eosinophilia in a Patient with Follicular Lymphoma Treated with Bendamustine plus Rituximab
por: Jo, Tatsuro, et al.
Publicado: (2014)

Large B - Cell Lymphoma of the Leg – Unfavourable Course with Rituximab/Bendamustin
por: Wollina, Uwe, et al.
Publicado: (2019)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
por: Alderuccio, Juan Pablo, et al.
Publicado: (2022)

Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
por: Cheson, Bruce D., et al.
Publicado: (2016)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
por: Vacirca, Jeffrey L., et al.
Publicado: (2013)

Paraneoplastic acute fibrinous and organizing pneumonia from lymphoma completely responding to bendamustine‐rituximab
por: Crowhurst, Thomas, et al.
Publicado: (2020)

Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study
por: Yamasaki, Satoshi, et al.
Publicado: (2021)

Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
por: Tisi, Maria Chiara, et al.
Publicado: (2023)

Successful Treatment of Factor X Deficiency in a Patient with Lymphoplasmacytic Lymphoma with Bendamustine Plus Rituximab Regimen: A Case Report and Literature Review
por: Rungjirajittranon, Tarinee, et al.
Publicado: (2021)

Bendamustine/dexamethasone/rituximab: Cytomegalovirus reactivation : case report
Publicado: (2021)

Bendamustine/rituximab: COVID-19 pneumonia: case report
Publicado: (2021)

Bendamustine/rituximab: Neutropenia, fever and inflammation: case report
Publicado: (2022)

Two rare cases of bronchus‐associated lymphoid tissue lymphoma successfully treated with rituximab‐bendamustine
por: Panitz, Nydia, et al.
Publicado: (2021)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

Rituximab/bendamustine/cytarabine for transplant‐eligible patients with mantle cell lymphoma: A retrospective study
por: Shimizu, Yuki, et al.
Publicado: (2023)

Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
por: Autore, Francesco, et al.
Publicado: (2020)

The genetic and cultural evolution of unsustainability
por: Snyder, Brian F.
Publicado: (2020)

The unsustainable anachronism of tuberculosis diagnosis
por: The Lancet Microbe
Publicado: (2023)

Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report
por: Zhou, Zhencang, et al.
Publicado: (2022)

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study
por: Michallet, Anne-Sophie, et al.
Publicado: (2018)

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
por: Sehn, Laurie H., et al.
Publicado: (2022)

An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma
por: Darwish, Mona, et al.
Publicado: (2014)

Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease
por: Mondello, Patrizia, et al.
Publicado: (2014)

Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
por: Lane, Michael A., et al.
Publicado: (2015)

Salvage chemotherapy with R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) for the treatment of relapsed primary CNS lymphoma
por: Cho, Min-Seok, et al.
Publicado: (2016)

Patients with marginal zone dural lymphoma successfully treated with rituximab and bendamustine: A report of two cases
por: Tsutsumi, Yutaka, et al.
Publicado: (2021)

A dramatic presentation of an unusual form of cutaneous lymphoma
por: Yang, Sam Shiyao, et al.
Publicado: (2015)

Prognostic role of translocator protein and oxidative stress markers in chronic lymphocytic leukemia patients treated with bendamustine plus rituximab
por: DE ROSA, ANIELLO, et al.
Publicado: (2015)

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases
por: Visentin, Andrea, et al.
Publicado: (2017)

Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab
por: Rai, Shinya, et al.
Publicado: (2018)

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
por: Ruppert, Amy S., et al.
Publicado: (2021)

Bendamustine and Rituximab, as First Line Treatment, in Intermediate, High Risk Splenic Marginal Zone Lymphomas of Elderly Patients
por: Castelli, Roberto, et al.
Publicado: (2016)

Isolated intracardiac recurrence of diffuse large B-cell lymphoma successfully treated with rituximab and bendamustine chemotherapy regimen
por: Chang, CH, et al.
Publicado: (2020)

Acute Pancreatitis Induced by Polatuzumab-Vedotin-Piiq in Combination With Bendamustine and Rituximab for Diffuse Large B-Cell Lymphoma
por: Anderson, Kara, et al.
Publicado: (2020)

Unsustainability of Obesity: Metabolic Food Waste
por: Serafini, Mauro, et al.
Publicado: (2016)

Perforating Folliculitis Secondary to Bendamustine-Rituximab Chemotherapy: A Case Report
por: Monteiro, Rowan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_111bu4a6c1ebr024onek4ji1id